124 related articles for article (PubMed ID: 20003834)
1. Hypertension and hemostatic/fibrinolytic balance disorders.
Tabak O; Gelisgen R; Uzun H; Kalender B; Balci H; Curgunlu A; Simsek G; Karter Y
Clin Invest Med; 2009 Dec; 32(6):E285. PubMed ID: 20003834
[TBL] [Abstract][Full Text] [Related]
2. White coat hypertension and haemostatic/fibrinolytic balance disorders.
Makris T; Stavroulakis G; Papadopoulos D; Paizis I; Krespi P; Tsoukala C; Hatzizacharias A; Votteas V
Eur Cytokine Netw; 2006 Jun; 17(2):137-41. PubMed ID: 16840033
[TBL] [Abstract][Full Text] [Related]
3. Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma.
Urano T; Kojima Y; Takahashi M; Serizawa K; Sakakibara K; Takada Y; Takada A
Jpn J Physiol; 1993; 43(2):221-8. PubMed ID: 8355419
[TBL] [Abstract][Full Text] [Related]
4. Impaired fibrinolysis and insulin resistance in patients with hypertension.
Jeng JR; Sheu WH; Jeng CY; Huang SH; Shieh SM
Am J Hypertens; 1996 May; 9(5):484-90. PubMed ID: 8735180
[TBL] [Abstract][Full Text] [Related]
5. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
Johansson L; Jansson JH; Boman K; Nilsson TK; Stegmayr B; Hallmans G
Stroke; 2000 Jan; 31(1):26-32. PubMed ID: 10625711
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension.
Sakata K; Shirotani M; Yoshida H; Urano T; Takada Y; Takada A
Am Heart J; 1999 Jun; 137(6):1094-9. PubMed ID: 10347337
[TBL] [Abstract][Full Text] [Related]
8. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.
Tarighi B; Kurum T; Demir M; Azcan SN
Can J Cardiol; 2007 Jun; 23(8):651-5. PubMed ID: 17593991
[TBL] [Abstract][Full Text] [Related]
9. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
Thögersen AM; Jansson JH; Boman K; Nilsson TK; Weinehall L; Huhtasaari F; Hallmans G
Circulation; 1998 Nov; 98(21):2241-7. PubMed ID: 9826309
[TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
11. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
12. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
[TBL] [Abstract][Full Text] [Related]
13. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol.
Jansson JH; Johansson B; Boman K; Nilsson TK
J Intern Med; 1991 Apr; 229(4):309-16. PubMed ID: 1902868
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
[TBL] [Abstract][Full Text] [Related]
15. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension.
Jern S; Wall U; Bergbrant A; Selin-Sjögren L; Jern C
Arterioscler Thromb Vasc Biol; 1997 Dec; 17(12):3376-83. PubMed ID: 9437182
[TBL] [Abstract][Full Text] [Related]
16. Progressive intermittent claudication is associated with impaired fibrinolysis.
Killewich LA; Gardner AW; Macko RF; Hanna DJ; Goldberg AP; Cox DK; Flinn WR
J Vasc Surg; 1998 Apr; 27(4):645-50. PubMed ID: 9576077
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic system in normotensive subjects and hypertensive patients.
Armas-Hernández MJ; Hernández-Hernández R; Armas-Padilla MC; Sosa-Canache B; Cammarata R; Pacheco B; Guerrero-Pajuelo J; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):177-82. PubMed ID: 17414587
[TBL] [Abstract][Full Text] [Related]
18. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension.
Altman R; Scazziota A; Rouvier J; Gurfinkel E; Favaloro R; Perrone S; Fareed J
Clin Cardiol; 1996 Jul; 19(7):549-54. PubMed ID: 8818435
[TBL] [Abstract][Full Text] [Related]
19. The effect of chronic allograft rejection on plasma regulators of fibrinolysis.
Perkowska A; Elhasade A; Durlik M; Placha G; Gałazka Z; Lao M; Gaciong Z
Ann Transplant; 2002; 7(1):44-51. PubMed ID: 12221903
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden.
Eliasson M; Jansson JH; Nilsson P; Asplund K
J Hypertens; 1997 Apr; 15(4):349-56. PubMed ID: 9211169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
